Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2

JAMA Neurol. 2021 Nov 1;78(11):1409-1411. doi: 10.1001/jamaneurol.2021.3287.

Abstract

This study establishes rates of Guillain-Barré syndrome relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.

Publication types

  • Letter

MeSH terms

  • Adult
  • BNT162 Vaccine
  • COVID-19 Vaccines / adverse effects*
  • Electronic Health Records
  • Female
  • Follow-Up Studies
  • Guillain-Barre Syndrome / chemically induced*
  • Guillain-Barre Syndrome / epidemiology
  • Humans
  • Israel / epidemiology
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Recurrence
  • Retrospective Studies

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine